CSIMarket Company Name, Ticker, Suppliers, else..
 
Arcutis Biotherapeutics Inc   (NASDAQ: ARQT)
 
Price: $23.7050 $0.33 1.390%
Day's High: $24.18000030517578 Week Perf: -0.82 %
Day's Low: $ 23.59 30 Day Perf: -9.8 %
Volume (M): 288,261 52 Wk High: $ 31.77
Volume (M$): $ 0 52 Wk Avg: $24.73
Open: $23.63 52 Wk Low: $16.57



 Market Capitalization (Millions $) 3,221
 Shares Outstanding (Millions) 136
 Employees 354
 Revenues (TTM) (Millions $) 464
 Net Income (TTM) (Millions $) 62
 Cash Flow (TTM) (Millions $) -19
 Capital Exp. (TTM) (Millions $) 10

Business Description


Arcutis Biotherapeutics Inc is a pharmaceutical company focused on developing and commercializing innovative immunology and dermatology therapies to treat immune-mediated dermatological diseases, including psoriasis, atopic dermatitis, and seborrheic dermatitis. The company was founded in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics' pipeline includes several dermatology drug candidates, including ARQ-252, a topical treatment for chronic hand eczema that is currently in Phase 3 clinical trials; ARQ-154, a topical cream for the treatment of seborrheic dermatitis that has completed Phase 2 clinical trials and is expected to enter Phase 3 trials; and ARQ-171, a topical foam formulation currently in Phase 2 clinical trials for the treatment of atopic dermatitis.

The company's lead product candidate is ARQ-151, a topical cream for the treatment of plaque psoriasis. ARQ-151 received FDA approval in December 2020 and became available on the market in February 202

Beyond its dermatology pipeline, Arcutis Biotherapeutics is developing ARQ-531, a small-molecule inhibitor for the treatment of B-cell malignancies and other blood cancers. ARQ-531 is currently in Phase 1 clinical trials.

Arcutis Biotherapeutics has partnered with several leading pharmaceutical companies, including LEO Pharma and SQ Innovation, to advance its pipeline and bolster its research and development efforts. The company's goal is to provide innovative and effective treatments for patients suffering from dermatological diseases, and to become a leading player in the dermatology and immunology markets.


   Company Address: 3027 Townsgate Road Westlake Village 91361 CA
   Company Phone Number: 418-5006   Stock Exchange / Ticker: NASDAQ ARQT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ   -3.42%    
MNKD   -4.29%    
MRK   -5.04%    
PFE   -4.46%    
TEVA   -1.47%    
VTRS   -2.95%    
• View Complete Report
   



Clinical Study

Safety and Efficacy Evaluation of Roflumilast Cream 0.05% in Infants with Atopic Dermatitis Insights from the INTEGUM...

Published Thu, Nov 13 2025 1:46 PM UTC

: Arcutis Biotherapeutics, Inc. has completed enrollment for its Phase 2 clinical trial, INTEGUMENT-INFANT, assessing the safety and efficacy of ZORYVE (roflumilast) cream 0.05% in infants diagnosed with atopic dermatitis (AD). This study is part of Arcutis broader clinical development program for roflumilast, which has shown promise in other dermatological applications, in...
Clinical Study

Arcutis Biotherapeutics Aims to Expand ZORYVE Use in Pediatric Psoriasis, Stock Performance Reflects Optimism

Published Wed, Sep 3 2025 4:10 PM UTC

Arcutis Biotherapeutics Inc., a leading dermatology-focused biopharmaceutical company, has recently submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) to expand the indication of ZORYVE (roflumilast) cream 0.3%. The aim is to include children ages 2 to 5 years in the treatment for plaque psoriasis, a chronic autoimmun...
Shares

Binding Talent with Innovation: Arcutis Biotherapeutics Strategic Deployment of Stock Units as a Recruitment Driver,

Published Fri, May 2 2025 8:00 PM UTC

Harnessing Talent: Arcutis Biotherapeutics Strategic Stock Unit Grants as a Recruitment CatalystIn the competitive world of biotechnology, where innovation and talent acquisition are key drivers of success, Arcutis Biotherapeutics, Inc. a commercial-stage biopharmaceutical company, has shown a strategic commitment to enhancing its workforce. By leveraging an inducement appr...
Shares

Arcutis Biotherapeutics Utilizes Nasdaq Rule 5635(c)(4) to Attract New Talent with Strategic Inducement Grants,

Published Wed, Mar 5 2025 9:00 PM UTC

Arcutis Biotherapeutics Grants Inducement Awards Under Nasdaq Rule 5635(c)(4): A Strategic Move for Empowering New TalentWestlake Village, Calif. Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a renowned commercial-stage biopharmaceutical company specializing in cutting-edge innovations in immuno-dermatology, continues to make impactful strides in the sector with their comm...
Shares

Arcutis Biotherapeutics Boosts Talent Acquisition with Strategic Grant of Stock Units Amidst Ongoing Growth Initiatives

Published Mon, Jan 6 2025 9:00 PM UTC

In a significant announcement made on January 6, 2025, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a company dedicated to pioneering advancements in immuno-dermatology, unveiled the issuance of 75,500 restricted stock units (RSUs) to eight newly hired employees. This proactive incentive strategy, approved by the Compensation Committee of the Board of Directors, aligns with...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 107.75
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 6.94
Price to Sales (Expected) -
Price to Book 14.6
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.49
Working Capital Ratio 3.01
Leverage Ratio (MRQ) 1.22
Total Debt to Equity 0.53
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.08

Per Share Current
Earnings (TTM) 0.22 $
Revenues (TTM) 3.41 $
Cash Flow (TTM) -
Cash 1.76 $
Book Value 1.62 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,310,681
Net Income per Employee (TTM) 176,147
Receivable Turnover Ratio (TTM) 3.31
Inventory Turnover Ratio (TTM) 1.35
Asset Turnover Ratio (TTM) 1.05

Profitability Ratios Current
Gross Margin (MRQ) 91.58 %
Operating Margin (MRQ) 12.65 %
Net Margin (MRQ) 23.22 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 4.74 %

Management Effectiveness Current
Return On Assets (TTM) 14.14 %
Return On Investment (TTM) 20.77 %
Return On Equity (TTM) 32.92 %
Dividend Yield -
Pay out Ratio (TTM) -



Arcutis Biotherapeutics Inc's Segments
ZORYVE cream 0.3%    52.36 % of total Revenue
ZORYVE foam    90.1 % of total Revenue
ZORYVE cream 0.15%    35.4 % of total Revenue
ZORYVE cream 0.05%    3.3 % of total Revenue
Reportable    181.16 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.